Hangzhou-based New Horizon Health Ltd (HKG: 6606) has announced the successful registration of three of its medical products with the Department of Health in the Hong Kong Special Administrative Region, facilitated through the Medical Device Administrative Control System (MDACS). This development marks a significant expansion of the company’s reach and impact within the healthcare sector.
Product Details and Implications for Healthcare
The registered products include a proprietary non-invasive fecal FIT-DNA colorectal cancer screening test, which utilizes fecal DNA to detect colorectal cancer. This innovative approach offers a less invasive method for early cancer detection compared to traditional procedures. Additionally, the company has registered a proprietary non-invasive fecal FIT screening product designed to test for hemoglobin biomarkers associated with colorectal cancer. This product further enhances the suite of non-invasive diagnostic tools available to healthcare providers.
Consumer Self-Test Product for Helicobacter Pylori
New Horizon Health has also registered a consumer self-test product for screening Helicobacter pylori based on fecal samples. This self-test product allows for convenient and private screening for H. pylori, a bacteria commonly associated with gastritis, peptic ulcer disease, and an increased risk of gastric cancer.-Fineline Info & Tech
Leave a Reply